On November 25, 2020 ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer reported the Company will be presenting at the Evercore ISI 3rd Annual HealthCONx Conference (Press release, ESSA, NOV 25, 2020, https://www.prnewswire.com/news-releases/essa-pharma-to-participate-at-evercore-isi-3rd-annual-healthconx-conference-301180096.html [SID1234571759]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. David. R. Parkinson, Chief Executive Officer, will present a corporate overview of the Company’s business. Dr. Parkinson along with ESSA’s Chief Operating Officer, Peter Virsik, and Chief Financial Officer, David S. Wood will be available for one-on-one meetings from December 1 – 3, 2020.

The presentations will be webcast live and can be accessed through the Investor Relations page at www.essapharma.com. A replay of the presentations will be available on the Company’s website for 90 days.

On November 25, 2020 Protagonist Therapeutics, Inc. (NASDAQ: PTGX) reported that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30 to December 3, 2020 (Press release, Protagonist, NOV 25, 2020, View Source [SID1234571758]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available for registered attendees via the Piper Sandler conference site until December 3, 2020, and will also be available November 30, 2020, by visiting the Investors section of the Protagonist Therapeutics website at View Source

On November 25, 2020 Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, reported that Sirtex with the support of its shareholder, China Grand Pharmaceutical and Healthcare Holdings Limited (CGP), has been notified of the acceptance by the National Medical Products Administration (NMPA) of the People’s Republic of China of its new drug application (NDA) of SIR-Spheres Y-90 resin microspheres (Press release, Sirtex Medical, NOV 25, 2020, View Source [SID1234571757]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With the NDA acceptance and according to relevant regulations on the review period for NDAs by the NMPA, Sirtex expects to receive a decision on the approval of SIR-Spheres for commercialization in China in the fourth quarter of 2021. However, the duration of approval procedures and final approval is subject to various factors. The indication included in the NDA is for the treatment of unresectable metastatic colorectal cancer (mCRC) in combination with fluorouridine adjuvant chemotherapy. In August this year, CGP and Sirtex received approval to file the NDA based on existing clinical trial data.

"We celebrate this achievement in our journey to provide a valuable treatment option to people with liver tumors from mCRC in China," said Kevin R. Smith, Chief Executive Officer of Sirtex. "We express deep thanks to the members of CGP, Sirtex China and our Global Regulatory, Quality Assurance, Operations and Medical teams as they navigated the regulatory process and secured acceptance of the NDA by the NMPA."

According to China’s cancer statistics in 2015, the number of new cases of colorectal cancer in China is 376,300, of which more than half of the patients (around 188,000) are likely to have liver metastasis. In addition, the broader liver cancer treatment market is even larger, as according to the World Health Organization statistics in 2018, there were 841,000 new cases of HCC worldwide, of which 400,000 occurred in China, accounting for 47.6% of the total cases. This demonstrates the long-term prospects for the Sirtex entry of SIR-Spheres in China.

On November 25, 2020 IsoPlexis, the leader in single-cell functional proteomics, reported that Chief Executive Officer and Co-Founder, Sean Mackay, will present at Evercore ISI’s 3rd Annual HealthCONx Conference on Wednesday, December 2nd at 9:40 a.m. ET (Press release, IsoPlexis, NOV 25, 2020, https://www.prnewswire.com/news-releases/isoplexis-to-present-at-evercore-isis-3rd-annual-healthconx-conference-on-december-2-2020-301180662.html [SID1234571756]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be made available on the company’s website at isoplexis.com.

On November 25, 2020 Amgen (NASDAQ:AMGN) reported that it will present at the Evercore ISI Virtual HealthCONx Conference at 1:50 p.m. ET on Tuesday, Dec. 1, 2020. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference (Press release, Amgen, NOV 25, 2020, https://www.prnewswire.com/news-releases/amgen-to-present-at-the-evercore-isi-virtual-healthconx-conference-301180785.html [SID1234571755]). Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!